Diethylcarbamazine (DEC) pretreatment reduced lung tissue damage. DEC inhibited the production of inflammatory markers in the lungs and BALF. DEC prevents NF-κB activation and IkBa phosphorylation. DEC attenuates neutrophil accumulation by stimulation of apoptosis. DEC accelerates the resolution of inflammation and may be a potential pharmacological treatment for ALI.